Clinical trials: Myopic Choroidal Neovascularisation
Nearsightedness
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
The purpose of this study is to gain a better understanding of the retinal vascular changes that occur in response to the optical effect of a myopic defocus daily disposable soft contact lens (MDSL) in a group of healthy young…
- Trial name
- NCT06527274
- Testing
- Experimental: Myopic defocus soft lens design (MDSL), Active Comparator: Single vision soft lens design (SVSL
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia
Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia
The purpose of this protocol is to determine wether the initial protocol in the treatment of subfoveal choroidal neovascularization associated to High Myopia with bevacizumab intravitreal injections is more effective when using 3…
- Trial name
- BENEMCOR (NCT01716026)
- Testing
- Bevazizumab intravitreal injection
- Where
- 11 sites in Spain
- Volunteers
- 66 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Choroidal Neovascularization
Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc
- Trial name
- NCT00370786
- Testing
- bevacizumab
- Where
- Iran
- Volunteers
- 31 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Pathologic Myopia
High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)
This research project intends to observe patients with high myopia who show pathological retinal changes, in order to evaluate more data on the risk factors for developing mCNV within this research project population in Germany.
- Trial name
- HELP (NCT03070717)
- Testing
- Observation & Diagnosis
- Where
- 26 sites in Germany
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Pathological Myopia
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- NCT01217944
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 74 sites in Austria, Canada and 18 more
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Myopic Choroidal Neovascularisation
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age.
- Trial name
- NCT03971162
- Testing
- 3+PRN, 6+PRN
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Myopic Choroidal Neovascularisation
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With mCNV.
- Trial name
- NCT04222842
- Testing
- CM082
- Where
- China
- Volunteers
- 96 people
- Sponsor
- AnewPharma
Myopia, Choroidal Neovascularization
Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia
The purpose of this study is to determine the efficacy and safety of intravitreal injections of bevacizumab in High Myopia´s choroidal neovascularization versus the standard treatment of Photodynamic therapy.
- Trial name
- NCT00967850
- Testing
- Intravitreal Injection, Photodynamic Therapy (Visudyne)
- Where
- 7 sites in Spain
- Volunteers
- 56 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Myopic Choroidal Neovascularisation
OCTA Changes in Choroidal Neovascularization in High Myopia
To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..
- Trial name
- NCT06357559
- Testing
- OCTA
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Pathologic Myopia
Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia
The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.
- Trial name
- COAST_UAmCNV (NCT03963596)
- Testing
- Intravitreal injection
- Where
- 3 sites in Ukraine
- Volunteers
- 122 people
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
Myopic Choroidal Neovascularisation, Anti-VEGF Treatment
The Treatment Burden of Myopic Choroidal Neovascularization
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue.
- Conditions
- Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
- Trial name
- mCNV burden (NCT07009574)
- Testing
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Policlinico Gaspare Rodolico - San Marco Catania
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
- Trial name
- NCT07550504
- Testing
- SB11 PFS
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Diabetic Retinopathy, Myopia
OCTA Metrics Repeatability and Reproducibility in Different Disorders
Retinal imaging is a corner stone in diagnosis of most retinal disorders. Standard imaging techniques e.g. fluorescein angiography and color fundus photography have a lot of limitations including limited resolution, invasive…
- Conditions
- Diabetic Retinopathy, Myopia, Choroidal Neovascularization, Healthy
- Trial name
- NCT04488887
- Testing
- Optical coherence tomography angiography
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tanta University
Pathologic Myopia
Brolucizumab for CNV Associated With Pathologic Myopia
The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.
- Trial name
- COASTUAbaCNV (NCT04976244)
- Testing
- Intravitreal injection
- Where
- 4 sites in Ukraine
- Volunteers
- 50 people
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Retinal Diseases, Choroidal Disease
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly…
- Conditions
- Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy
- Trial name
- NCT06918028
- Testing
- With fundus diseases, Without fundus diseases
- Where
- China
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Choroidal Neovascularization, Degenerative Myopia
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV).
- Conditions
- Choroidal Neovascularization, Degenerative Myopia, Pathological Myopia
- Trial name
- NCT00407719
- Testing
- Bevacizumab
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Myopia, Pathological
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial.
- Trial name
- Myrror (NCT01249664)
- Testing
- VEGF Trap-Eye (BAY86-5321), No Drug
- Where
- 20 sites in Hong Kong, Japan and 3 more
- Volunteers
- 122 people
- Sponsor
- Bayer
Myopic Choroidal Neovascularization
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
To evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
- Trial name
- NCT00797992
- Testing
- Injection
- Where
- Brazil
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- Brilliance (NCT01922102)
- Testing
- Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT
- Where
- 47 sites in China, Hong Kong and 4 more
- Volunteers
- 457 people
- Sponsor
- Novartis Pharmaceuticals